<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01436968</url>
  </required_header>
  <id_info>
    <org_study_id>PrTK03</org_study_id>
    <nct_id>NCT01436968</nct_id>
  </id_info>
  <brief_title>Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer</brief_title>
  <acronym>PrTK03</acronym>
  <official_title>A Randomized Controlled Trial of ProstAtak® as Adjuvant to Up-front Radiation Therapy For Localized Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Advantagene, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Advantagene, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness of ProstAtak® immunotherapy in
      combination with radiation therapy for patients with intermediate-high risk localized
      prostate cancer. ProstAtak kills tumor cells and stimulates a cancer vaccine effect. Killing
      tumor cells in an immune stimulatory environment induces the body's immune system to detect
      and destroy cancer cells. ProstAtak has shown synergy with radiation without added toxicity
      and lower than expected recurrence rates in previous clinical trials. The hypothesis is that
      ProstAtak can lead to improvement in the clinical outcome for patients with prostate cancer.
      Participants will be randomized to the ProstAtak or control arm at a 2:1 ratio. Both arms
      receive standard external beam radiation therapy. Short-term androgen deprivation therapy may
      be given but is not required.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2011</start_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival defined as the time from randomization until the date of the first failure event will be compared for the ProstAtak® arm versus the placebo control arm. The analyses will be based on the intent to treat population.</measure>
    <time_frame>Assessed at each visit every 6 months through year 5 until event occurs.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prostate cancer specific survival and overall survival will be compared for the ProstAtak® arm versus the placebo control arm.</measure>
    <time_frame>Assessed at each visit every 6 months through year 5 after which long-term follow up of general health status will continue yearly.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA nadir will be compared for the ProstAtak® arm versus the placebo control arm.</measure>
    <time_frame>Assessed at each visit every 6 months through year 5.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported Health Related Quality of Life outcomes will be collected using the Expanded Prostate Cancer Index Composite (EPIC-26) questionnaire. The change in QOL over time will be compared for the ProstAtak® arm versus the placebo control arm.</measure>
    <time_frame>Assessed at baseline and at 3, 6, 12, 18 and 24 months after completion of radiation.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The safety profile will be characterized by collection of adverse event information and laboratory values during the treatment phase (until the completion of radiation). Data on late effects will be collected after radiation completion.</measure>
    <time_frame>Assessed at each visit and continuously throughout the study.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">711</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>ProstAtak®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ProstAtak® (AdV-tk) + valacyclovir + radiation therapy +/- ADT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo + valacyclovir + radiation therapy +/- ADT</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ProstAtak®(AdV-tk) + valacyclovir</intervention_name>
    <description>Patients will receive three courses of ProstAtak® each consisting of AdV-tk injection + oral valacyclovir. AdV-tk injection will be delivered to the prostate via trans-rectal ultrasound guided injection as follows:
The first injection will be given at least 15 days and not more than 8 weeks before starting radiation.
The second injection will be 0-3 days before initiation of radiation therapy.
The third injection will be 15-22 days after the 2nd injection.
The prodrug, valacyclovir, will be administered at a fixed dose for 14 days after each AdV-tk injection.
Standard external beam radiation therapy will be delivered to the prostate. Short-term androgen deprivation therapy (maximum of 6 months) is optional but must be decided before enrollment to allow for stratification.</description>
    <arm_group_label>ProstAtak®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo + valacyclovir</intervention_name>
    <description>Patients will receive three courses each consisting of placebo injection + oral valacyclovir. Placebo injection will be delivered to the prostate via trans-rectal ultrasound guided injection as follows:
The first injection will be given at least 15 days and not more than 8 weeks before starting radiation.
The second injection will be 0-3 days before initiation of radiation therapy.
The third injection will be 15-22 days after the 2nd injection.
The prodrug, valacyclovir, will be administered at a fixed dose for 14 days after each placebo injection.
Standard external beam radiation therapy will be delivered to the prostate. Short-term androgen deprivation therapy (maximum of 6 months) is optional but must be decided before enrollment to allow for stratification.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria include:

          -  Localized prostate cancer meeting the NCCN criteria of Intermediate Risk or patients
             having only one NCCN high-risk feature

               -  NCCN Intermediate Risk is defined as having at least one of the following: PSA
                  10-20 ng/ml, Gleason score =7, T2b-T2c

               -  High Risk with a single high risk feature is defined as having only one of the
                  following: PSA&gt;20 ng/ml, Gleason score 8-10, or T3a

               -  Excluded are those in the following risk groups: Low risk; High risk with more
                  than 1 high risk factor; Locally advanced/very high risk=T3b-T4; Metastatic: N1
                  or M1

          -  Planning to undergo standard prostate-only external beam radiation therapy

          -  ECOG Performance Status 0-2

        Exclusion Criteria include:

          -  Liver disease, including known cirrhosis or active hepatitis

          -  Patients on systemic corticosteroids (&gt;10mg prednisone per day) or other
             immunosuppressive drugs

          -  Known HIV+ patients

          -  Regional lymph node involvement or distant metastases

          -  Patients planning to receive whole pelvic irradiation

          -  Prior treatment for prostate cancer, except TURP or ADT. For ADT, it may only be given
             for a maximum of 6 months

          -  Patients who had or plan to have orchiectomy as the form of hormonal ablation

          -  Known sensitivity or allergic reactions to acyclovir or valacyclovir
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Arizona Oncology Services Foundation</name>
      <address>
        <city>Multiple Locations</city>
        <state>Arizona</state>
        <zip>85260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Precision Radiation Oncology</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Kim, MD</last_name>
      <phone>949-381-5800</phone>
      <email>paul.kim@procancercare.com</email>
    </contact>
    <investigator>
      <last_name>Paul Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Foothills Urology</name>
      <address>
        <city>Golden</city>
        <state>Colorado</state>
        <zip>80401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Aggers</last_name>
      <phone>303-985-2550</phone>
      <email>deb@foothillhsurologypc.com</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Quinn</last_name>
      <phone>303-985-2550</phone>
      <email>jennifer@foothillsurologypc.com</email>
    </contact_backup>
    <investigator>
      <last_name>David Cahn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Urology</name>
      <address>
        <city>Parker</city>
        <state>Colorado</state>
        <zip>80134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sibley Memorial Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jo Hurtt</last_name>
      <phone>202-660-5772</phone>
      <email>jhurtt2@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Curtiland Deville, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>21st Century Oncology</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peggy Mouradian, LPN</last_name>
      <phone>954-370-7555</phone>
      <email>peggy.mouradian@21co.com</email>
    </contact>
    <investigator>
      <last_name>Eric S. Chenven, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>21st Century Oncology</name>
      <address>
        <city>Lakewood Ranch</city>
        <state>Florida</state>
        <zip>34202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Richman</last_name>
      <phone>941-907-9053</phone>
      <email>kathleen.richman@21co.com</email>
    </contact>
    <investigator>
      <last_name>John Sylvester, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>21st Century Oncology</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brittney Decker, RN</last_name>
      <phone>239-430-3297</phone>
      <email>brittney.decker@21co.com</email>
    </contact>
    <investigator>
      <last_name>Chaundre K. Cross, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>21st Century Oncology</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peggy Mouradian, LPN, CCRC</last_name>
      <phone>954-370-7555</phone>
      <email>Peggy.Mouradian@21co.com</email>
    </contact>
    <investigator>
      <last_name>Christopher T. Chen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Johns Hopkins University School of Medicine, The Sidney Kimmel Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Leitzel, RN</last_name>
      <phone>410-502-9242</phone>
      <email>Jvogel10@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Terry Caldwell</last_name>
      <phone>443-287-1889</phone>
      <email>caldwte@jhmi.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Theodore DeWeese, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Walter Reed National Military Medical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20889</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judith A. Travis, RN, CCRC</last_name>
      <phone>301-319-2927</phone>
      <email>judith.a.travis.ctr@mail.mil</email>
    </contact>
    <investigator>
      <last_name>Inger L. Rosner, MD, MC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Medical School</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret R Humphries, RN, CCRC</last_name>
      <phone>508-856-5711</phone>
      <email>Margaret.Humphries@umassmed.edu</email>
    </contact>
    <investigator>
      <last_name>Mitchell H. Sokoloff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VA Sierra Nevada Health Care System</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barak Perahia, MD</last_name>
      <phone>775-786-7200</phone>
      <phone_ext>3400</phone_ext>
      <email>barak.perahia@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Jeannine Shuster, BN, RN</last_name>
      <phone>775-326-2784</phone>
      <email>jeannine.shuster@va.gov</email>
    </contact_backup>
    <investigator>
      <last_name>Barak Perahia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Mexico Oncology Hematology Consultants (NMOHC)</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Lee</last_name>
      <phone>505-822-3851</phone>
      <email>CLee@nmcca.org</email>
    </contact>
    <contact_backup>
      <last_name>Andrea Yost</last_name>
      <phone>505-243-4039</phone>
      <email>research@nmohc.com</email>
    </contact_backup>
    <investigator>
      <last_name>Gregg Franklin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Cancer Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Gibson</last_name>
      <phone>505-272-5237</phone>
      <email>mngibson@salud.unm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Susan Lopez</last_name>
      <phone>505-925-0375</phone>
      <email>slopez@salud.unm.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Thomas M. Schroeder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Radiation Centers of New York</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Primiano</last_name>
      <phone>516-932-6008</phone>
      <email>mprimiano@imppllc.com</email>
    </contact>
    <investigator>
      <last_name>Shawn H. Zimberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Radiation Centers of New York</name>
      <address>
        <city>Hartsdale</city>
        <state>New York</state>
        <zip>10530</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Primiano</last_name>
      <phone>516-932-6008</phone>
      <email>mprimiano@imppllc.com</email>
    </contact>
    <investigator>
      <last_name>Shawn H. Zimberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Radiation Centers of New York</name>
      <address>
        <city>Hauppauge</city>
        <state>New York</state>
        <zip>11749</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Primiano</last_name>
      <phone>516-932-6008</phone>
      <email>mprimiano@imppllc.com</email>
    </contact>
    <investigator>
      <last_name>Shawn H. Zimberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Radiation Centers of New York (Integrated Medical Professionals)</name>
      <address>
        <city>North Hills</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Primiano</last_name>
      <phone>516-394-9600</phone>
      <email>mprimiano@imppllc.com</email>
    </contact>
    <investigator>
      <last_name>Shawn H. Zimberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Radiation Centers of New York</name>
      <address>
        <city>Plainview</city>
        <state>New York</state>
        <zip>11803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Primiano</last_name>
      <phone>516-932-6008</phone>
      <email>mprimiano@imppllc.com</email>
    </contact>
    <investigator>
      <last_name>Shawn H. Zimberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Associated Medical Professionals of NY, PLLC</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Faisal</last_name>
      <phone>315-558-6619</phone>
      <email>sfaisal@ampofny.com</email>
    </contact>
    <investigator>
      <last_name>Neil F. Mariados, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Radiation Centers of New York</name>
      <address>
        <city>West Nyack</city>
        <state>New York</state>
        <zip>10994</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Primiano</last_name>
      <phone>516-932-6008</phone>
      <email>mprimiano@imppllc.com</email>
    </contact>
    <investigator>
      <last_name>Shawn H. Zimberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southwest Urology, Clinical Research Solutions</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Heider, BS</last_name>
      <phone>440-340-9010</phone>
      <email>sheider@crssites.com</email>
    </contact>
    <investigator>
      <last_name>Michael T Berte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Urology Institute</name>
      <address>
        <city>Springfield</city>
        <state>Oregon</state>
        <zip>97477</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renee Podesta</last_name>
      <phone>514-284-5508</phone>
      <email>rpodesta@oregonurology.com</email>
    </contact>
    <contact_backup>
      <last_name>Danna Cardenas</last_name>
      <phone>514-284-5508</phone>
      <email>danna@oregonurology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Bryan Mehlhaff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lancaster Urology</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dawn Stern</last_name>
      <phone>717-393-1771</phone>
      <phone_ext>4544</phone_ext>
      <email>dawns@lancuro.com</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Nonnemacher</last_name>
      <phone>717-393-1771</phone>
      <phone_ext>4544</phone_ext>
      <email>jennifern@lancuro.com</email>
    </contact_backup>
    <investigator>
      <last_name>Paul Sieber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leanne Schimke</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111-2497</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital, Allegheny Health Network</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Park Bogan</last_name>
      <phone>412-359-3748</phone>
      <email>Park.Bogan@AHN.ORG</email>
    </contact>
    <contact_backup>
      <last_name>Andrea Fabian, RN</last_name>
      <phone>412-359-6452</phone>
      <email>andrea.fabian@ahn.org</email>
    </contact_backup>
    <investigator>
      <last_name>Russell Fuhrer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Triangle Urological Group, Allegheny Health Network</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Park Bogan</last_name>
      <phone>412-359-3748</phone>
      <email>Park.Bogan@AHN.ORG</email>
    </contact>
    <contact_backup>
      <last_name>Andrea Fabian, RN</last_name>
      <phone>412-359-6452</phone>
      <email>andrea.fabian@ahn.org</email>
    </contact_backup>
    <investigator>
      <last_name>Ralph J Miller, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ralph H. Johnson Veterans Affairs Medical Center</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Caulder, RN, MSN, CCRC</last_name>
      <phone>843-789-7816</phone>
      <email>Susan.caulder@va.gov</email>
    </contact>
    <investigator>
      <last_name>Stephen J. Savage, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urology Clinics of North Texas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Dr. Irving Fishman's Office</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Houston Willowbrook Radiation Oncology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77070</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maegan Elliott</last_name>
      <phone>281-351-5174</phone>
      <email>Maegan.elliott@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Chase Authement</last_name>
      <phone>281-351-5174</phone>
      <email>Chase.Authement@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Abhilasha Patel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr. Ned Stein's Office</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>South Texas San Antonio VA Healthcare System</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-4404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catrine Garcia</last_name>
      <phone>210-617-5300</phone>
      <phone_ext>14498</phone_ext>
      <email>catrinel.garcia@va.gov</email>
    </contact>
    <investigator>
      <last_name>Michael Liss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>William Jones, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Millennium Radiation Center - The Woodlands</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77380</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maegan Elliott</last_name>
      <phone>281-351-5174</phone>
      <email>Maegan.elliott@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Chase Authement</last_name>
      <phone>281-351-5174</phone>
      <email>Chase.Authement@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jason Berilgen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Urology Specialists</name>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <zip>77375</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maegan Glass</last_name>
      <phone>281-351-5174</phone>
      <email>Maegan.Glass@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Chase Authement</last_name>
      <phone>281-351-5174</phone>
      <email>Chase.authement@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Steven W. Sukin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2011</study_first_submitted>
  <study_first_submitted_qc>September 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2011</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>immunotherapy, cytotoxicity, tumor vaccine, prostate cancer, radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valacyclovir</mesh_term>
    <mesh_term>Acyclovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

